Back to Research

Organization profile

Altamira Therapeutics

Altamira Therapeutics is a clinical-stage biopharmaceutical organization focused on developing peptide-based nanoparticle technologies for the extrahepatic delivery of RNA therapeutics. The company utilizes its proprietary xPhore and CycloPhore platforms to target indications such as KRAS-driven cancer and rheumatoid arthritis while divesting legacy assets in consumer health and CNS.

Basel, SwitzerlandFounded 2003

Overview

1. Executive Summary (Confidence: High)

Altamira Therapeutics is currently undergoing a radical strategic repositioning, shifting its focus from legacy clinical development in inner ear and allergic rhinitis to becoming a "leading provider of innovative RNA delivery technology".[21] The organization’s value proposition is built upon its proprietary "xPhore" platform (encompassing OligoPhore and SemaPhore), which utilizes a patented peptide to deliver siRNA and mRNA to extrahepatic tissues—a major bottleneck in the RNA industry.[21] Despite a turbulent 2024–2025 marked by a transition from Nasdaq to the OTCQB marketplace and a critically low cash position (reporting only $4,000 as of June 2025), Altamira continues to advance its flagship AM-401 program toward an IND submission.[22] Its "picks and shovels" strategy involves out-licensing its platform to biopharma partners and spinning off its RNA delivery business into a separate subsidiary (ATAG) to attract private equity funding.[22]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.